-transparent.png){kind=logo}
The recent identification of tumor-associated antigens (TAA) and TAA-derived peptides presented by MHC molecules to T cells has provided the tools to design and test clinical vaccines for treating human malignancies, such as melanoma. While the most effective adjuvant for use in vaccine formulation remains unclear, autologous dendritic cells (DC) appear to be good candidate adjuvants. We have previously shown that syngeneic bone marrow-derived DC when pulsed ex vivo with relevant TAA-derived peptides can effectively vaccinate mice against a subsequent challenge with tumor or can effectively treat animals bearing established tumors. In this report, we have engineered murine interleukin-12 (mIL-12), a potent stimulator of cell-mediated immunity, into murine DC using retroviral-mediated or plasmid-based transfection procedures. Transfectants produced up to 25 ng rIL-12/10(6) cells/48 hours. These engineered cells are capable of promoting enhanced anti-tumor, antigen-specific CTL responses compared to nontransduced DC.
L Zitvogel, and
B Couderc, and
J I Mayordomo, and
P D Robbins, and
M T Lotze, and
W J Storkus
January 1997,
Advances in experimental medicine and biology,
L Zitvogel, and
B Couderc, and
J I Mayordomo, and
P D Robbins, and
M T Lotze, and
W J Storkus
January 2006,
Letters in drug design & discovery,
L Zitvogel, and
B Couderc, and
J I Mayordomo, and
P D Robbins, and
M T Lotze, and
W J Storkus
September 2016,
Iranian journal of immunology : IJI,
L Zitvogel, and
B Couderc, and
J I Mayordomo, and
P D Robbins, and
M T Lotze, and
W J Storkus
December 2009,
Cancer gene therapy,
L Zitvogel, and
B Couderc, and
J I Mayordomo, and
P D Robbins, and
M T Lotze, and
W J Storkus
March 2014,
Liver international : official journal of the International Association for the Study of the Liver,
L Zitvogel, and
B Couderc, and
J I Mayordomo, and
P D Robbins, and
M T Lotze, and
W J Storkus
June 2004,
Cancer biotherapy & radiopharmaceuticals,
L Zitvogel, and
B Couderc, and
J I Mayordomo, and
P D Robbins, and
M T Lotze, and
W J Storkus
January 1997,
Stem cells (Dayton, Ohio),
L Zitvogel, and
B Couderc, and
J I Mayordomo, and
P D Robbins, and
M T Lotze, and
W J Storkus
September 1999,
Methods (San Diego, Calif.),
L Zitvogel, and
B Couderc, and
J I Mayordomo, and
P D Robbins, and
M T Lotze, and
W J Storkus
January 1997,
Advances in experimental medicine and biology,
L Zitvogel, and
B Couderc, and
J I Mayordomo, and
P D Robbins, and
M T Lotze, and
W J Storkus
August 2022,
Nanoscale,
